GeneDx is trading 4% down today at $63.47 as the stock faces pressure from broader biotech sector weakness and lingering sentiment from its recent financial disclosures.
- The move follows a period of volatility triggered by the company's disappointing Q1 2026 results, which included a reduced revenue outlook and subsequent legal scrutiny.
- Today's decline appears driven by a risk-off environment in the broader market rather than any new company-specific catalysts or announcements.
- The stock had recently experienced a sharp rebound from its post-earnings selloff before today's retracement.